Business

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR1803 Injection Combined with Anti-CD38 Monoclonal Antibody for Indications of Adult Patients with Relapsed/Refractory Multiple Myeloma

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR1803 Injection Combined with Anti-CD38 Monoclonal Antibody for Indications of Adult Patients with Relapsed/Refractory Multiple Myeloma

articleChongqing Genrix Biopharmaceutical Co., Ltd. Class AJuly 2, 20254/news/announcement-on-voluntary-disclosure-of-obtaining-notice-of-approval-for-drug-clinical-trial-of-gr1803-injection-combined-with-anti-cd38-monoclonal-antibody-for-indications-of-adult-patients-with-relapsedrefractory-multiple-myeloma
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR1803 Injection Combined with Anti-CD38 Monoclonal Antibody for Indications of Adult Patients with Relapsed/Refractory Multiple Myeloma

About this update from Chongqing Genrix Biopharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR1803 Injection Combined with Anti-CD38 Monoclonal Antibody for Indications of Adult Patients with Relapsed/Refractory Multiple MyelomaThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Chongqing Genrix Biopharmaceutical Co., Ltd. Class A